Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects

[1]  Jinghua Yan,et al.  Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants , 2022, Emerging microbes & infections.

[2]  R. Rottier,et al.  SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination , 2022, Cell Research.

[3]  Cameron R. Wolfe,et al.  A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus , 2021, Science Translational Medicine.

[4]  J. Butterton,et al.  Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients , 2021, The New England journal of medicine.

[5]  D. Easton,et al.  Covid-19 Vaccine Effectiveness in New York State , 2021, The New England journal of medicine.

[6]  Hualiang Jiang,et al.  Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2 , 2021, Cell Research.

[7]  L. Du,et al.  Neutralizing antibodies for the prevention and treatment of COVID-19 , 2021, Cellular & Molecular Immunology.

[8]  K. Gajiwala,et al.  An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 , 2021, Science.

[9]  Zhuorong Li,et al.  Advancement of prodrug approaches for nucleotide antiviral agents. , 2021, Current topics in medicinal chemistry.

[10]  M. Hassany,et al.  Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. , 2021, JAMA.

[11]  P. Rocchi,et al.  Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting , 2020, Molecular Cell.

[12]  R. Haubrich,et al.  Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  M. Gismondo,et al.  Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status , 2020, Pharmacological Research.

[14]  Erwan L'Her,et al.  Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.

[15]  R. Baric,et al.  Small-Molecule Antiviral β-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance , 2019, Journal of Virology.

[16]  K. Seley‐Radtke,et al.  The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold , 2018, Antiviral Research.

[17]  Katherine L. Seley‐Radtke,et al.  The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold , 2018, Antiviral Research.